Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Samantha Bowyer,Prashanth Prithviraj,Paul Lorigan,James Larkin,Grant A. McArthur,Victoria Atkinson,Michael Millward,Muoi Khou,Stefan Diem,S. Ramanujam,Ben Kong,Elizabeth Liniker,Alexander Guminski,Phillip Parente,Miles C. Andrews,Sagun Parakh,Jonathan Cebon,Georgina V. Long,Matteo S. Carlino,Oliver Klein

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

2017

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’

Keywords:

Antibody
Medicine
Melanoma
Immunology
Ipilimumab
Toxicity
CTLA-4
in patient
anti ctla 4
metastatic melanoma
Internal medicine
anti pd 1
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations